| gap-debate-20260410- | Do pathological protein condensates in neurodegeneration share recruitment mecha | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What physicochemical properties determine selective protein recruitment vs exclu | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Can mitochondrial-cytosolic proteostasis coupling be enhanced without disrupting | open | 0.70 | 0.00 | 2026-04-10 | 0 | | mitochondrial-biology |
| gap-debate-20260410- | What lysosomal pH range optimizes pathological seed degradation without generati | open | 0.85 | 0.00 | 2026-04-10 | 0 | | cellular-proteostasis |
| gap-debate-20260410- | How does membrane lipid composition quantitatively affect pathological seed upta | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | Do chaperones selectively recognize pathological vs physiological protein confor | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | protein-biochemistry |
| gap-debate-20260410- | Do CTD phosphatase inhibitors selectively reduce dilncRNA synthesis without glob | open | 0.80 | 0.00 | 2026-04-10 | 0 | | transcriptional-regulation |
| gap-debate-20260410- | What is the druggable binding interface between RAD50 and TBP that enables PPI d | open | 0.75 | 0.00 | 2026-04-10 | 0 | | structural-biology |
| gap-debate-20260410- | How can dilncRNA-mediated condensate formation be distinguished from physiologic | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | What are the conserved secondary structures in dilncRNAs that enable selective t | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Can engineered protein scaffolds cross the blood-brain barrier without disruptin | open | 0.75 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | Do disease mutations primarily cause loss of compartmentalization or gain-of-fun | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the druggable allosteric sites on neuronal protein interaction hub prot | open | 0.85 | 0.00 | 2026-04-10 | 0 | | structural-biology |
| gap-debate-20260410- | How can subcellular compartmentalization defects be measured as biomarkers in li | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-debate-20260410- | Which tissue-specific biomarkers can stratify patients for personalized tissue-t | open | 0.70 | 0.00 | 2026-04-10 | 0 | | precision-medicine |
| gap-debate-20260410- | Can metabolic reprogramming achieve sufficient tissue selectivity to avoid off-t | open | 0.75 | 0.00 | 2026-04-10 | 0 | | metabolism |
| gap-debate-20260410- | What determines the threshold effects and cooperative binding dynamics that gove | open | 0.80 | 0.00 | 2026-04-10 | 0 | | systems-biology |
| gap-debate-20260410- | How do tissue-specific chaperone networks determine differential vulnerability t | open | 0.85 | 0.00 | 2026-04-10 | 0 | | protein-folding |
| gap-debate-20260409- | Which specific post-translational modifications on pathological tau create drugg | partially_addressed | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260409- | Do tau-containing vesicles exhibit unique surface glycosylation patterns that di | partially_addressed | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260409- | Can nanobodies achieve selective membrane penetration into tau-containing vesicl | partially_addressed | 0.78 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260409- | What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie | partially_addressed | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-discovery |
| gap-pubmed-20260406- | How do dilncRNAs specifically drive molecular crowding and phase separation of D | partially_addressed | 0.79 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines the specificity of DDR protein recruitment to dilncRNA-induced c | partially_addressed | 0.77 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What molecular mechanisms drive tissue-specific phenotypes in Mendelian neurolog | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do protein-protein interactions determine subcellular localization and funct | partially_addressed | 0.77 | 0.00 | 2026-04-06 | 0 | | synaptic-biology |
| gap-pubmed-20260406- | What neural circuits encode and maintain multi-generational migratory route memo | partially_addressed | 0.65 | 0.00 | 2026-04-06 | 0 | | spatial-memory |
| gap-pubmed-20260406- | How does ADCY8 mechanistically regulate long-term memory formation in migratory | partially_addressed | 0.73 | 0.00 | 2026-04-06 | 0 | | memory-and-navigation |
| gap-pubmed-20260406- | What are the neuron-specific effects of ALS-causing mutations on autophagy machi | partially_addressed | 0.77 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What mechanisms underlie neuronal resistance to autophagy induction compared to | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa | partially_addressed | 0.76 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do host cell factors influence the conformation and propagation properties o | partially_addressed | 0.76 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What molecular mechanisms determine the conformational diversity and strain-like | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines the selectivity and efficiency of intercellular transmission pat | partially_addressed | 0.74 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What mechanisms drive TDP-43 pathology specifically in Alzheimer's disease versu | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What mechanisms underlie TDP-43's contribution to cognitive impairment severity | partially_addressed | 0.78 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How does APOE4 mechanistically increase TDP-43 pathology frequency in Alzheimer' | partially_addressed | 0.82 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | Why do structurally diverse sugars (trehalose, melibiose, lactulose) produce ide | partially_addressed | 0.79 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How does controlled lysosomal membrane permeabilization induce autophagy without | partially_addressed | 0.85 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines the specificity of calcium-dependent PPP3/calcineurin activation | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How does chronic cGAS/STING activation downstream of TDP-43 contribute to progre | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | What upstream mechanisms cause TDP-43 to trigger mPTP opening and can this be th | partially_addressed | 0.79 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines the specificity of TDP-43-induced mitochondrial DNA release for | partially_addressed | 0.82 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines organelle-specific autophagy selectivity in neurodegenerative di | partially_addressed | 0.76 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How do different organelle-specific autophagy pathways coordinate during neurode | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | What determines the selectivity of complement-mediated synaptic elimination in p | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | synaptic-biology |
| gap-pubmed-20260406- | How does sevoflurane-induced NF-κB activation specifically trigger complement ca | partially_addressed | 0.79 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | Why does prolonged anesthesia cause both cognitive dysfunction and anxiety throu | partially_addressed | 0.74 | 0.00 | 2026-04-06 | 0 | | neurodegeneration |
| gap-pubmed-20260406- | How does SPI1 transcriptionally regulate C1QA and C1QC expression in atheroscler | partially_addressed | 0.75 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |
| gap-pubmed-20260406- | What are the specific molecular mechanisms by which C1Q components drive atheros | partially_addressed | 0.80 | 0.00 | 2026-04-06 | 0 | | neuroinflammation |